A 32-year-old woman from rural Maharashtra attends a cervical cancer screening camp. Her Pap smear shows atypical squamous cells of undetermined significance (ASCUS). HPV testing is positive for high-risk HPV-16. She is asymptomatic with no abnormal vaginal discharge. What is the most appropriate next step in management?

## Management of ASCUS with High-Risk HPV Positivity **Key Point:** When ASCUS is accompanied by high-risk HPV positivity (HPV-16 or HPV-18), the risk of underlying CIN2+ is significantly elevated (approximately 25–40%), and colposcopy is mandated. ### Rationale for Colposcopy **High-Yield:** ASCUS + HR-HPV = colposcopy. This combination carries a substantially higher risk than ASCUS alone, where observation with repeat cytology is acceptable. **Clinical Pearl:** HPV-16 and HPV-18 are the most oncogenic types and account for ~70% of cervical cancers. Detection of these types in the setting of cytologic abnormality warrants immediate visualization of the cervix. ### Management Algorithm ```mermaid flowchart TD A[ASCUS on Pap smear]:::outcome --> B{HPV test result?}:::decision B -->|HR-HPV positive| C[Colposcopy with directed biopsy]:::action B -->|HR-HPV negative| D[Repeat cytology in 12 months]:::action C --> E{Biopsy findings?}:::decision E -->|CIN1| F[Observation or ablation]:::action E -->|CIN2/3| G[LEEP or cold knife conization]:::action E -->|Normal| H[Return to routine screening]:::action ``` ### Why Colposcopy is Superior to Repeat Cytology - **Direct visualization:** Allows identification of acetowhite lesions, punctation, and mosaic patterns - **Tissue diagnosis:** Biopsy confirms presence or absence of CIN and excludes invasive disease - **Risk stratification:** Histology guides definitive treatment (ablation vs. excision) - **Time efficiency:** Avoids 12-month delay in a high-risk patient **Mnemonic:** **ASCUS-HPV** = **Always Colposcope (to rule out) Serious Underlying Squamous lesions** [cite:Park 26e Ch 14]